Boston Scientific Corporation  

(Public, NYSE:BSX)   Watch this stock  
Find more results for BSX
9.30
+0.19 (2.14%)
Real-time:   2:30PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 9.12 - 9.38
52 week 4.79 - 9.38
Open 9.15
Vol / Avg. 13.34M/19.42M
Mkt cap 14.41B
P/E     -
Div/yield     -
EPS -3.21
Shares 1.55B
Beta 1.17
Inst. own 76%
Jul 24, 2013
Q2 2013 Boston Scientific Corporation Earnings Release Add to calendar
May 15, 2013
Boston Scientific Corporation at Bank of America Merrill Lynch Health Care Conference - Webcast
May 7, 2013
Boston Scientific Corporation Annual Shareholder Meeting
Apr 25, 2013
Q1 2013 Boston Scientific Corporation Earnings Conference Call - Webcast
Apr 17, 2013
Q1 2013 Boston Scientific Corporation Earnings Release
Feb 26, 2013
Boston Scientific Corporation at RBC Capital Markets' Healthcare Conference - Webcast
Feb 25, 2013
Boston Scientific Corporation at Citi Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin -20.10% -56.12%
Operating margin -18.74% -53.36%
EBITD margin - 28.05%
Return on average assets -8.37% -21.16%
Return on average equity -21.24% -44.65%
Employees 24,000 -
Carbon Disclosure Rating - 37/100

Address

One Boston Scientific Place
NATICK, MA 01760
United States - Map
+1-508-6508000 (Phone)
+1-508-6508923 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia
Discussion Group - Google Finance

Description

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. During the year ended December 31, 2011, its products were offered for sale by seven core businesses: Interventional Cardiology, CRM, Endoscopy, Peripheral Interventions, Urology/Women�s Health, Neuromodulation, and Electrophysiology. In January 2011, it completed the acquisition of Intelect Medical, Inc. In January 2011, it completed the acquisition of Sadra Medical, Inc. In March 2011, the Company completed the acquisition of Atritech, Inc. In February 2011, it announced the acquisitions of S.I. Therapies and ReVascular Therapeutics, Inc. In January 2011, the Company sold its Neurovascular business to Stryker Corporation. In June 2012, the Company acquired Cameron Health, Inc. of San Clemente, California and, as a result, added to its product portfolio subcutaneous implantable cardioverter defibrillator, called the S-ICD System.

Officers and directors

Peter M. Nicholas Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
Michael F. Mahoney President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Jeffrey D. Capello Chief Financial Officer, Executive Vice President
Age: 48
Bio & Compensation  - Reuters
Timothy A. Pratt Chief Administrative Officer, Executive Vice President, General Counsel, Secretary
Age: 63
Bio & Compensation  - Reuters
Supratim Bose Executive Vice President and President, Asia-Pacific
Age: 60
Bio & Compensation  - Reuters
Keith D. Dawkins M.D. Global Chief Medical Officer, Executive Vice President
Age: 62
Bio & Compensation  - Reuters
Michael P. Phalen Executive Vice President and President - MedSurg
Age: 53
Bio & Compensation  - Reuters
Kenneth J. Pucel Executive Vice President - Global Operations, Quality and Technology
Age: 46
Bio & Compensation  - Reuters
Jean Fitterer Lance Chief Compliance Officer, Senior Vice President
Age: 51
Bio & Compensation  - Reuters
Wendy Carruthers Senior Vice President - Human Resources
Age: 44
Bio & Compensation  - Reuters